สแกนเพื่อดาวน์โหลด
แพลตฟอร์มตรวจสอบ # และยืนยันการกำกับดูแลของตลาดการเงินทั่วโลก

Binance bStocks pass xStocks as second-largest tokenized stock issuer

บทคัดย่อ:Binance‘s bStocks have become the second-largest tokenized stock issuer by value less than two months after launch, surpassing xStocks while still trailing Ondo Finance. On Aug. 3, bStocks stood at about $624 million, ahead of xStocks at roughly $579 million but behind Ondo at about $927 million; as of Tuesday, bStocks remained second at $610.6 million versus xStocks’ $601.2 million. The market has shifted dramatically: a year earlier, xStocks led with $40.7 million, followed by Robinhood, while Ondo held only about $65,000. Total tracked value has surged from roughly $80 million to about $2.7 billion. Binance launched bStocks on June 11, and co-founder Changpeng Zhao attributed its growth to Binances user base.

Binance bStocks have overtaken xStocks to become the second-largest tokenized stock issuer by value less than two months after launch.

BStocks reached about $624 million on Aug. 3, surpassing xStocks at roughly $579 million but trailing Ondo Finance at about $927 million, according to Token Terminal data. As of Tuesday, bStocks remained in second place at $610.6 million, narrowly ahead of xStocks at $601.2 million.

The issuer landscape has shifted sharply as the tokenized stock market has grown. A year earlier, xStocks led with $40.7 million, followed by Robinhood at $37.2 million, while Ondo held about $65,000. The total value tracked by Token Terminal has since surged from roughly $80 million to about $2.7 billion.

Tokenized stock value by issuer on Aug. 3, 2025, Aug. 2, 2026 and Aug. 3, 2026. Source: Token Terminal

Binance launched bStocks on June 11 to give investors exposure to US stocks through blockchain-based tokens without directly owning the underlying shares.

Changpeng Zhao, Binance‘s co-founder and former CEO, attributed bStocks’ rapid growth to Binances user base.

ข้อจำกัดความรับผิดชอบ

มุมมองในบทความนี้แสดงถึงมุมมองส่วนตัวของผู้เขียนเท่านั้นและไม่ถือเป็นคำแนะนำในการลงทุน สำหรับแพลตฟอร์มนี้ไม่รับประกันความถูกต้องครบถ้วนและทันเวลาของข้อมูลบทความ และไม่รับผิดชอบต่อการสูญเสียใด ๆ ที่เกิดจากการใช้ข้อมูลในบทความ
บทความก่อนหน้า

ซีอีโอ Novo Nordisk ยอมรับ Eli Lilly เพิ่มส่วนแบ่งตลาด หุ้นร่วง